M. Gao, R. Nettles, M. Belema, L. Snyder, V. Nguyen et al., Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect, Nature, vol.77, issue.7294, pp.96-100, 2010.
DOI : 10.1038/nature08960

R. Fridell, D. Qiu, C. Wang, L. Valera, and M. Gao, Resistance Analysis of the Hepatitis C Virus NS5A Inhibitor BMS-790052 in an In Vitro Replicon System, Antimicrobial Agents and Chemotherapy, vol.54, issue.9, pp.3641-50, 2010.
DOI : 10.1128/AAC.00556-10

M. Sofia, D. Bao, W. Chang, J. Du, D. Nagarathnam et al., -methyluridine Nucleotide Prodrug (PSI-7977) for the Treatment of Hepatitis C Virus, Journal of Medicinal Chemistry, vol.53, issue.19, pp.7202-7220, 2010.
DOI : 10.1021/jm100863x

M. Bifano, C. Hwang, B. Oosterhuis, J. Hartstra, D. Grasela et al., Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir., Antiviral Therapy, vol.18, issue.7, pp.931-971, 2013.
DOI : 10.3851/IMP2674

M. Bifano, H. Sevinsky, C. Hwang, H. Kandoussi, H. Jiang et al., Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate, Antiviral Therapy, vol.19, issue.5, pp.511-520, 2014.
DOI : 10.3851/IMP2718

M. Sulkowski, D. Gardiner, M. Rodriguez-torres, K. Reddy, T. Hassanein et al., Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection, New England Journal of Medicine, vol.370, issue.3
DOI : 10.1056/NEJMoa1306218

I. Jacobson, S. Gordon, K. Kowdley, E. Yoshida, M. Rodriguez-torres et al., Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options, New England Journal of Medicine, vol.368, issue.20
DOI : 10.1056/NEJMoa1214854

J. Rockstroh, M. Puoti, and M. Rodriguez-torres, Sofosbuvir and Ribavirin Therapy for the Treatment of HIV/HCV Coinfected Patients With HCV GT 1-4 Infection: The PHOTON 1 and 2 Trials, Hepatology, vol.60, issue.A195, p.87, 2014.

J. Molina, C. Orkin, D. Iser, F. Zamora, M. Nelson et al., Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study, The Lancet, vol.385, issue.9973, pp.1098-106, 2015.
DOI : 10.1016/S0140-6736(14)62483-1

M. Charlton, E. Gane, M. Manns, R. Brown, . Jr et al., Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation, Gastroenterology, vol.148, issue.1, pp.108-125, 2015.
DOI : 10.1053/j.gastro.2014.10.001

A. Hcv, Recommendations for testing, managing, and treating hepatitis C

V. Chulanov, K. Zhdanov, and K. Kersey, Sofosbuvir plus Ribavirin for the Treatment of Russian Patients with Chronic HCV Genotype 1 or 3 infection, Hepatology, vol.60, issue.A982, p.134, 2014.

P. Ruane, D. Ain, R. Stryker, R. Meshrekey, M. Soliman et al., Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry, Journal of Hepatology, vol.62, issue.5, pp.1040-1046, 2015.
DOI : 10.1016/j.jhep.2014.10.044

W. Doss, G. Shiha, M. Hassany, R. Soliman, R. Fouad et al., Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4, Journal of Hepatology, vol.63, issue.3, pp.581-586, 2015.
DOI : 10.1016/j.jhep.2015.04.023

D. Dieterich, B. Bacon, and S. Flamm, Evaluation of sofosbuvir and simeprevir-based regimens in the TRIO network: academic and community treatment of a real-world, heterogeneous population, Hepatology, vol.60, issue.A46, p.55, 2014.

J. Reddy, J. Lim, A. Kuo, D. Bisceglie, A. Vargas et al., O007 : All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: Interim report from the HCV-target real world experience, Journal of Hepatology, vol.62, issue.A007, p.183, 2015.
DOI : 10.1016/S0168-8278(15)30014-3

V. Saxena, F. Koraishy, M. Sise, J. Lim, R. Chung et al., LP08 : Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with reduced renal function: Real-world experience from HCV-target, Journal of Hepatology, vol.62, issue.LP08, p.263, 2015.
DOI : 10.1016/S0168-8278(15)30162-8

Z. Younossi, M. Stepanova, S. Pol, J. Bronowicki, M. Carrieri et al., The impact of ledipasvir/sofosbuvir on patient-reported outcomes in cirrhotic patients with chronic hepatitis C: the SIRIUS study, Liver International, vol.39, issue.Suppl 1, 2009.
DOI : 10.1097/01.mcg.0000142583.00102.45